Literature DB >> 11840338

Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFalpha cytotoxicity.

M Craig Caldwell1, Colleen Hough, Stefanie Fürer, W Marston Linehan, Patrice J Morin, Myriam Gorospe.   

Abstract

We have used serial analysis of gene expression (SAGE) to investigate the influence of the von Hippel-Lindau (VHL) gene on global gene expression profiles. SAGE libraries were prepared from renal cell carcinoma (RCC) lines that either lack (parental) or express wild-type VHL (wtVHL). Comparison of these libraries revealed some differentially expressed genes (Glut-1, for example) that were known to be influenced by VHL, but the majority of genes had not previously been reported to be affected by the cell's VHL status. The identification of several genes involved in TNFalpha-mediated events prompted us to compare the sensitivity of cells with different VHL status in TNFalpha cytotoxicity assays. Strikingly, VHL-deficient cells were much more resistant to the toxic influence of TNFalpha. We propose that VHL-dependent sensitization of RCC cells to TNFalpha-mediated killing may contribute to VHL's growth suppressive function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840338     DOI: 10.1038/sj.onc.1205140

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.

Authors:  Eijiro Nakamura; Paula Abreu-e-Lima; Yasuo Awakura; Takahiro Inoue; Toshiyuki Kamoto; Osamu Ogawa; Hirokazu Kotani; Toshiaki Manabe; Guo-Jun Zhang; Keiichi Kondo; Vānia Nosé; William G Kaelin
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

2.  Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.

Authors:  Yozo Mitsui; Hiroaki Shiina; Taku Kato; Shigekatsu Maekawa; Yutaka Hashimoto; Marisa Shiina; Mitsuho Imai-Sumida; Priyanka Kulkarni; Pritha Dasgupta; Ryan Kenji Wong; Miho Hiraki; Naoko Arichi; Shinichiro Fukuhara; Soichiro Yamamura; Shahana Majid; Sharanjot Saini; Guoren Deng; Rajvir Dahiya; Koichi Nakajima; Yuichiro Tanaka
Journal:  Mol Cancer Res       Date:  2017-02-27       Impact factor: 5.852

3.  Molecular aspects of renal cell carcinoma: a review.

Authors:  Hari Koul; Jung-Sik Huh; Kyle O Rove; Luiza Crompton; Sweaty Koul; Randall B Meacham; Fernando J Kim
Journal:  Am J Cancer Res       Date:  2010-12-18       Impact factor: 6.166

Review 4.  Ubiquitin pathway in VHL cancer syndrome.

Authors:  Michael Ohh
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

5.  von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays.

Authors:  Stefanie Galbán; Jinshui Fan; Jennifer L Martindale; Chris Cheadle; Bryan Hoffman; Michael P Woods; Gretchen Temeles; Jürgen Brieger; Jochen Decker; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

6.  Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.

Authors:  Stefanie Galbán; Jennifer L Martindale; Krystyna Mazan-Mamczarz; Isabel López de Silanes; Jinshui Fan; Wengong Wang; Jochen Decker; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

7.  Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma.

Authors:  Fateme Tousi; Jonathan Bones; Othon Iliopoulos; William S Hancock; Marina Hincapie
Journal:  J Chromatogr A       Date:  2012-07-28       Impact factor: 4.759

8.  Ocular clusterin expression in von Hippel-Lindau disease.

Authors:  Min Zhou; Defen Shen; James E Head; Emily Y Chew; Patricia Chévez-Barrios; W Richard Green; Chi-Chao Chan
Journal:  Mol Vis       Date:  2007-11-15       Impact factor: 2.367

9.  pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2.

Authors:  Haifeng Yang; Yoji Andrew Minamishima; Qin Yan; Susanne Schlisio; Benjamin L Ebert; Xiaoping Zhang; Liang Zhang; William Y Kim; Aria F Olumi; William G Kaelin
Journal:  Mol Cell       Date:  2007-10-12       Impact factor: 17.970

10.  Full-Length Enrich c-DNA Libraries-Clear Cell-Renal Cell Carcinoma.

Authors:  Sai-Wen Tang; Jung-Yaw Lin
Journal:  J Oncol       Date:  2012-03-20       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.